Asia
Perennial Real Estate of Singapore announced a $1.2B joint venture to develop hospital-centered mixed-use developments in China.
Beijing’s Genetron Health, a precision medicine oncology company, raised over $61M in a Series C round led by Zhongjin Kangrui Medical Industrial Fund.
Zhejiang DTRM Biopharma announced a $60M Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase inhibitor.
Genostics will acquire China rights to Oncimmune’s blood-based cancer testing platform in return for a $13.5M investment into the UK-based company’s shares.
The financing was co-led by Advantech Capital and SDIC Venture Capital.
The agreement covers employees who agree to leave voluntarily.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
Sansure Biotech of Changsha raised $77M in a funding round led by Lilly Asia Ventures and Highlight Capital with participation from June Capital.
PRESS RELEASES